NCT04297436 (BexKPK) is a NA clinical trial of 4CMenB (Bexsero®) vaccine in Gonorrhea, sponsored by University of Oxford.

Who is sponsoring NCT04297436?

NCT04297436 is sponsored by University of Oxford.

What drugs are being tested in NCT04297436?

Interventions in NCT04297436: 4CMenB (Bexsero®) vaccine.

Is NCT04297436 still recruiting?

NCT04297436 is currently completed. Last updated 14 April 2022.

Last reviewed 2022-04-14 · How we verify

NCT04297436: BexKPK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gonococcal Vaccine Study in Key Populations in Kenya

Completed NA Last updated 14 April 2022

What this trial tests

NA trial testing 4CMenB (Bexsero®) vaccine in Gonorrhea in 50 participants. Completed in 28 February 2022.

Timeline

31 May 2021

Primary endpoint
5 February 2022

28 February 2022

Quick facts

Lead sponsor	University of Oxford
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	50
Start date	31 May 2021
Primary completion	5 February 2022
Estimated completion	28 February 2022
Sites	1 location across Kenya

Drugs / interventions tested

4CMenB (Bexsero®) vaccine — full drug profile →

Conditions studied

Gonorrhea — all drugs for Gonorrhea →

Sponsor

University of Oxford

Who can join

Adults 18 to 25, any sex, with Gonorrhea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Gonorrhoea is a sexually transmitted infection that can infect both men and women. It can cause infections in the genitals, rectum, and throat. It is a very common infection, especially among young people aged 18-25 years. Meningococcal disease and gonorrhoea are caused by bacteria that are closely related but cause different diseases that are spread in different ways. New evidence suggests that the Meningococcal B vaccine (Bexsero®) licensed outside of Kenya against meningococcal B disease may also be effective against gonorrhoea due to genetic similarities between the two organisms causing the two diseases. The aim of this study is to generate data to develop a gonorrhoea vaccine, using an existing vaccine against meningococcal disease

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Outer Membrane Vesicle Vaccine Platforms.
Micoli F, Adamo R, Nakakana U. · · 2024 · cited 43× · PMID 37796436 · DOI 10.1007/s40259-023-00627-0
<i>Neisseria gonorrhoeae</i> vaccines: a contemporary overview.
Williams E, Seib KL, Fairley CK, Pollock GL, et al · · 2024 · cited 41× · PMID 38226640 · DOI 10.1128/cmr.00094-23
Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
Abara WE, Kirkcaldy RD, Bernstein KT, Galloway E, et al · · 2025 · cited 30× · PMID 39082700 · DOI 10.1093/infdis/jiae383
Immune responses to <i>Neisseria gonorrhoeae</i> and implications for vaccine development.
Belcher T, Rollier CS, Dold C, Ross JDC, et al · · 2023 · cited 26× · PMID 37662926 · DOI 10.3389/fimmu.2023.1248613
Profiling IgG and IgA antibody responses during vaccination and infection in a high-risk gonorrhoea population.
Stejskal L, Thistlethwaite A, Ramirez-Bencomo F, Rashmi S, et al · · 2024 · cited 14× · PMID 39112489 · DOI 10.1038/s41467-024-51053-x
Bioengineering Outer-Membrane Vesicles for Vaccine Development: Strategies, Advances, and Perspectives.
Zahid A, Ismail H, Wilson JC, Grice ID. · · 2025 · cited 10× · PMID 40733744 · DOI 10.3390/vaccines13070767

Verify or expand the search:

Other trials of 4CMenB (Bexsero®) vaccine

Trials testing the same drug.

NCT04295733 — Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency · completed

Other recruiting trials for Gonorrhea

Currently open trials in the same condition.

NCT06738407 — Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections · Phase 4 · recruiting
NCT07397403 — The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand. · Phase 4 · recruiting
NCT06951438 — Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortio · NA · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04297436 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 14 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04297436.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing